Cannabis Market Giant Aurora Cannabis Buys TerraPharma in $38 Million Deal

The million-dollar merger between Aurora Cannabis and TerraPharma demonstrates the growth of the international industry in this sector. In exchange for $38 million in cash and stock, Aurora has acquired 100 percent of all existing rights to TerraFarma Inc. The group in question specializes in the cultivation, production, and distribution of medical cannabis and cannabis ingredients for adult-use, serving customers worldwide.

According to Aurora CEO Miguel Martin, in an interview with news portal HighlyCapitalized, the project dubbed Project Willow is expected to double the emphasis of his company’s premium brands, and could reach profitability as early as the first half of 2023.

Stay informed with the latest affairs about the world of hemp. One potentially useful cannabis news tool is Hemp.im app and its companion marijuana news website.

The sale was only concluded after Thrive spent nine months getting to know and studying Aurora Cannabis’ objectives

“The deal is really about leveraging our premium line through Thrive’s brilliant workforce,” said Martin.

The CEO also pointed out that should Thrive achieve its expected revenue targets for the next two years of the acquisition, its return could be up to $20 million in stock, cash, or both, i.e. an extraordinary gain given the short time frame and amount invested.

The sale was only concluded after Thrive spent nine months getting to know and studying Aurora’s objectives, thus ensuring that the brand would not put at risk its brands or its strong relationships with consumers. Another important fact, is that the company based in Ontario, Canada, was the first to launch a farmgate cannabis store, i.e. where cannabis is sold where it is grown.

“This allows us to increase brand recognition, introduce new items to the marketplace, and reach consumers we could never reach before,” reveals Thrive CEO Geoff Hoover when referring to the new partnership.

Hoover’s team will be responsible for playing an important role in Aurora Cannabis’ adult-use operations. Since cannabis was regulated for adult use in the country in 2018, brands that offer high-quality products like Thrive, have become more attractive to the consuming public, because by anticipating reduced costs with the farmgate project, producers have been able to compete with the illicit market of the plant, which has generated a lot of profitability for them.

Just to give you an idea, sales of cannabis products, such as flowers and their derivatives, grew 158% in 2021 alone, according to a survey released by BDSA, a company specializing in market data.

Aurora Cannabis has yet to grow its empire since buying Reliva, another industry giant, in 2020. However, the company has been consolidating and managing to face, on equal terms, giants such as Tilray, Aphria, and Hexo, which after a merger between them last year, came to dominate the Canadian market.

__

(Featured image by MurrPhoto via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Sechat, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us